Cyst Fluid Genomics Redefine Risk: Mixed-Type IPMNs Harbor Greater Malignant Potential Than Branch-Duct Variants
Highlights
The study reveals that mixed-type intraductal papillary mucinous neoplasms (IPMNs) are significantly more likely to harbor high-risk mutations (HRMs) such as TP53, SMAD4, and MTOR compared to branch-duct (BD) IPMNs (31% vs. 9.3%). Cyst fluid next-generation sequencing (NGS) using the PancreaSeq platform demonstrated a remarkable 100% specificity and 90% sensitivity in predicting advanced neoplasia within mixed-type IPMNs. These findings suggest that molecular analysis can effectively ‘upgrade’ or ‘downgrade’ clinical risk, potentially sparing patients from unnecessary surgery while identifying those at highest risk for progression to invasive carcinoma.
Introduction: The IPMN Management Dilemma
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.